MVI 816

Drug Profile

MVI 816

Alternative Names: PAP Vaccine - Madison Vaccines; pTVG-HP

Latest Information Update: 09 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Madison Vaccines
  • Class Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 25 Jul 2018 Madison Vaccines in collaboration with plans a phase II trial for Prostate Cancer (Recurrent) in September 2018 (NCT03600350)
  • 19 Aug 2015 Phase-II clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Treatment-resistant) in USA (Parenteral)
  • 23 Jun 2014 Madison Vaccines initiates expansion in a phase II trial in Prostate cancer (first-line therapy, hormone-naive patients) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top